The Role of Hormone Receptor Expression and Hormonal Therapy (Estrogen and Progesterone) in the Management and Prognosis of Meningiomas in Females: A Systematic Review
DOI:
https://doi.org/10.56570/jimgs.v2i2.110Keywords:
Meningioma, Hormone receptor, Estrogen receptor, Progesterone receptor, Hormonal therapy, Receptor expressionAbstract
Meningioma is the primary central nervous system tumour with the highest recorded prevalence. Research on meningiomas has shown an association with hormone receptor expression, but the underlying pathophysiologic mechanisms remain unclear. This systematic review presents the available information on the role of progesterone and estrogen in meningioma’s pathogenesis, prognosis, and treatment. The study used the Preferred Reporting Items for Systemic Review and MetaAnalysis (PRISMA) 2020 guidelines. The authors searched and downloaded relevant published articles from the following databases; PubMed, PubMed Central (PMC), MEDLINE, the Cochrane Library, and Google Scholar. The downloaded articles were screened using set eligibility criteria and appropriate quality appraisal tools and subsequently relevant data was extracted using standardized questionnaires. Based on the papers reviewed, progesterone receptor expression in meningioma is associated with significantly more favourable prognostic factors and treatment outcomes while a negative correlation exists between overall survival and the presence of estrogen receptors. In conclusion, analysing hormone receptor expression in meningioma appears necessary for targeted hormonal and endocrine therapy. A suitable reference population must also be defined in future extensive prospective multi-centre and multi-national clinical studies.References
Agopiantz, M., Carnot, M., Denis, C., Martin, E., & Gauchotte, G. (2023). Hormone Receptor Expression in Meningiomas: A Systematic Review. Cancers, 15(3), 980. https://doi.org/10.3390/cancers15030980.
Bernat, A. L., Oyama, K., Hamdi, S., Mandonnet, E., Vexiau, D., Pocard, M., George, B., & Froelich, S. (2015). Growth stabilization and regression of meningiomas after discontinuation of cyproterone acetate: a case series of 12 patients. Acta neurochirurgica, 157(10), 1741–1746. https://doi.org/10.1007/s00701-015-2532-3.
Butta, S., & Gupta, M. K. (2020). Study of epidemiological aspects and hormone receptor status of meningiomas. International Journal of Research in Medical Sciences, 8(7), 2482–2486. https://doi.org/10.18203/2320-6012.ijrms20202883.
Cetin, A., Lacin, S., Sogutcu, N. (2019). Progesterone Receptor Status May Be the Most Important Prognostic Factor for Meningiomas International Journal of Hematology and Oncology, 29 (1), 38-45. https://doi.org/10.4999/uhod.193115.
Cossu, G., Levivier, M., Daniel, R. T., & Messerer, M. (2015). The Role of Mifepristone in Meningiomas Management: A Systematic Review of the Literature. BioMed research international, 2015, 267831. https://doi.org/10.1155/2015/267831.
Girardelli, S., Albano, L., Mangili, G., Valsecchi, L., Rabaiotti, E., Cavoretto, P. I., Mortini, P., & Candiani, M. (2022). Meningiomas in Gynecology and Reproduction: An Updated Overview for Clinical Practice. Reproductive sciences (Thousand Oaks, Calif.), 29(9), 2452–2464. https://doi.org/10.1007/s43032-021-00606-2.
Hoisnard, L., Laanani, M., Passeri, T., Duranteau, L., Coste, J., Zureik, M., Froelich, S., & Weill, A. (2022). Risk of intracranial meningioma with three potent progestogens: A population-based case-control study. European Journal of Neurology, 29(9), 2801–2809. https://doi.org/10.1111/ene.15423.
Hortobágyi, T., Bencze, J., Murnyák, B., Kouhsari, M. C., Bognár, L., & Marko-Varga, G. (2017). Pathophysiology of Meningioma Growth in Pregnancy. Open Medicine (Warsaw, Poland), 12, 195–200. https://doi.org/10.1515/med-2017-0029.
Ichwan S, Santoso F, Aman R.A, Tandian D, Fachniadin A, Nugroho S.W. (2023). Estrogen and progesterone in meningioma: Bridging the gap of knowledge. Neurology Asia, 28(1), 1 – 11. https://doi.org/10.54029/2023wxj.
Janah, R., Rujito, L., & Wahyono, D. J. (2022). Expressions of Progesterone Receptor of Orbital Meningiomas in Indonesia. Asian Pacific Journal of cancer prevention: APJCP, 23(12), 4137–4143. https://doi.org/10.31557/APJCP.2022.23.12.4137.
Ji, J., Sundquist, J., & Sundquist, K. (2016). Association of tamoxifen with meningioma: a population-based study in Sweden. European Journal of cancer prevention: the official journal of the European Cancer Prevention Organisation (ECP), 25(1), 29–33. https://doi.org/10.1097/CEJ.0000000000000133.
Ji, Y., Rankin, C., Grunberg, S., Sherrod, A. E., Ahmadi, J., Townsend, J. J., Feun, L. G., Fredericks, R. K., Russell, C. A., Kabbinavar, F. F., Stelzer, K. J., Schott, A., & Verschraegen, C. (2015). Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 33(34), 4093–4098. https://doi.org/10.1200/JCO.2015.61.6490.
Karena, Z. V., Shah, H., Vaghela, H., Chauhan, K., Desai, P. K., & Chitalwala, A. R. (2022). Clinical Utility of Mifepristone: Apprising the Expanding Horizons. Cureus, 14(8), e28318. https://doi.org/10.7759/cureus.28318.
Ohba, S., Murayama, K., Nishiyama, Y., Adachi, K., Yamada, S., Abe, M., Hasegawa, M., Hirose, Y. (2019). Clinical and radiographic features for differentiating solitary fibrous tumor/hemangiopericytoma from meningioma. World Neurosurg pii: S1878-8750(19)31646-8. doi: 10.1016/j.wneu.2019.06.094.
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., Chou, R., Glanville, J., Grimshaw, J. M., Hróbjartsson, A., Lalu, M. M., Li, T., Loder, E. W., Mayo-Wilson, E., McDonald, S., McGuinness, L. A., … Moher, D. (2021). The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ (Clinical research ed.), 372, n71. https://doi.org/10.1136/bmj.n71.
Samarut, E., Lugat, A., Amelot, A., Scharbarg, E., Hadjadj, S., Primot, C., Loussouarn, D., Thillays, F., Buffenoir, K., Cariou, B., Drui, D., & Roualdes, V. (2021). Meningiomas and cyproterone acetate: a retrospective, monocentric cohort of 388 patients treated by surgery or radiotherapy for intracranial meningioma. Journal of neuro-oncology, 152(1), 115–123. https://doi.org/10.1007/s11060-020-03683-6.
Shu, X., Jiang, Y., Wen, T., Lu, S., Yao, L., & Meng, F. (2019). Association of hormone replacement therapy with increased risk of meningioma in women: A hospital-based multicenter study with propensity score matching. Asia-Pacific Journal of clinical oncology, 15(5), e147–e153. https://doi.org/10.1111/ajco.13138.
Touat, M., Lombardi, G., Farina, P., Kalamarides, M., & Sanson, M. (2014). Successful treatment of multiple intracranial meningiomas with the antiprogesterone receptor agent mifepristone (RU486). Acta neurochirurgica, 156(10), 1831–1835. https://doi.org/10.1007/s00701-014-2188-4.
Weill, A., Nguyen, P., Labidi, M., Cadier, B., Passeri, T., Duranteau, L., Bernat, A. L., Yoldjian, I., Fontanel, S., Froelich, S., & Coste, J. (2021). Use of high dose cyproterone acetate and risk of intracranial meningioma in women: cohort study. BMJ (Clinical research ed.), 372, n37. https://doi.org/10.1136/bmj.n37.
